A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method

dc.contributor.author	North, B	en_US
dc.contributor.author	Kocher, HM	en_US
dc.contributor.author	Sasieni, P	en_US
dc.date.accessioned	2020-05-22T14:12:13Z
dc.date.available	2019-06-06	en_US
dc.date.issued	2019-06-26	en_US
dc.identifier.issn	1471-2407	en_US
dc.identifier.other	ARTN 632	en_US
dc.identifier.uri	https://qmro.qmul.ac.uk/xmlui/handle/123456789/64289
dc.language.iso	en	en_US
dc.relation.ispartof	BMC CANCER	en_US
dc.rights	Creative Commons Attribution 4.0 International License
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.subject	Adaptive design	en_US
dc.subject	Bayesian adaptive	en_US
dc.subject	Simulation	en_US
dc.subject	3+3 design	en_US
dc.subject	Maximal tolerated dose	en_US
dc.subject	Dose-finding	en_US
dc.subject	CRM	en_US
dc.subject	Model-based design	en_US
dc.subject	Rule-based design	en_US
dc.title	A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method	en_US
dc.type	Article
dc.rights.holder	© The Author(s). 2019.
dc.identifier.doi	10.1186/s12885-019-5801-3	en_US
pubs.author-url	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473007000004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a	en_US
pubs.notes	Not known	en_US
pubs.publication-status	Published	en_US
pubs.volume	19	en_US
rioxxterms.funder	Default funder	en_US
rioxxterms.identifier.project	Default project	en_US

Except where otherwise noted, this item's license is described as Creative Commons Attribution 4.0 International License

Related items